Mobilization of stem cells by granulocyte colony-stimulating factor for the regeneration of myocardial tissue after myocardial infarction

Background and objective: Animal data suggest that mobilized bone marrow cells (BMC) may contribute to tissue regeneration after myocardial infarction (MI). However the safety, feasibility and efficacy of treatment with granulocyte colony-stimulating factor (G-CSF) to mobilize BMC after acute myocardial infarction in patients is unknown. We analysed cardiac function and perfusion in 5 patients who were treated with G-CSF in addition to standard therapeutical regimen.

Methods and results: 48 h after successful recanalization and stent implantation in 5 patients with acute MI, the patients received 10 mg/kg body weight/day G-CSF subcutaneously for a mean treatment duration of 7.6±0.5 days. Peak value of CD34+ cells, a multipotent subfraction of bone marrow cells, was reached after 5.0±0.7 days. After 3 months of follow-up global left ventricular ejection fraction (determined by radionuclideventriculography) increased significantly from 42.2±6.6 % to 51.6±8.3 % (P<0.05). The wall motion score and the wall perfusion score (determined by ECG gated SPECT) decreased from 13.5±3.6 to 9.9±3.5 (P<0.05) and from 9.6±2.9 to 7.0±4.5 (P<0.05), respectively, indicating a significant improvement of myocardial function and perfusion. No severe side effects of G-CSF treatment were observed. Malignant arrhythmias were not observed either.

Conclusion: In patients with acute MI, treatment with G-CSF to mobilize BMC appears to be well toleated under clinical conditions. Improved cardiac function and perfusion may be attributed to BMC-associated promotion of myocardial regeneration and neovascularization.

References

• 1 Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H. et al . Transplantation of Progenitor Cells and Regeneration Enhancem ent in Acute Myocardial Infarction (TOPCARE-AMI).  Circulation. 2002;  106 3009-3017
• 2 Cerqueira M D, Weissman N J, Dilsizian V, Jacobs A K, Kaul S, Laskey W K, Pennell D J, Rumberger J A, Ryan T, Verani M S. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.  Circulation. 2002;  105 539-542
• 3 Deb A, Wang S, Skelding K A, Miller D, Simper D, Caplice N M. Bone marrow-derived cardiomyocytes are present in adult human heart: A study of gender-mismatched bone marrow transplantation patients.  Circulation. 2003;  107 1247-1249
• 4 Frangogiannis N G, Smith C W, Entman M L. The inflammatory response in myocardial infarction.  Cardiovasc Res. 2002;  53 31-47
• 5 Goodell M A, Jackson K A, Majka S M, Mi T, Wang H, Pocius J, Hartley C J, Majesky M W, Entman M L, Michael L H. et al . Stem cell plasticity in muscle and bone marrow.  Ann N Y Acad Sci. 2001;  938 208-218 , discussion 218 - 20.
• 6 Grigg A P, Roberts A W, Raunow H, Houghton S, Layton J E, Boyd A W, McGrath K M, Maher D. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers.  Blood. 1995;  86 4437-4445
• 7 Han C I, Campbell G R, Campbell J H. Circulating bone marrow cells can contribute to neointimal formation.  J Vasc Res. 2001;  38 113-119
• 8 Kocher A A, Schuster M D, Szabolcs M J, Takuma S, Burkhoff D, Wang J, Homma S, Edwards N M, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function.  Nat Med. 2001;  7 430-436
• 9 Li R K, Mickle D A, Weisel R D, Rao V, Jia Z Q. Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury.  Ann Thorac Surg. 2001;  72 1957-193
• 10 Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc J M, Morice M C, Maillard L, Pansieri M. et al . Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.  N Engl J Med. 2001;  344 1895-1903
• 11 Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson S M, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine D M. et al . Bone marrow cells regenerate infarcted myocardium.  Nature. 2001;  410 701-705
• 12 Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine D M, Leri A, Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival.  Proc Natl Acad Sci U S A. 2001;  98 10344-10349
• 13 Quaini F, Urbanek K, Beltrami A P, Finato N, Beltrami C A, Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Chimerism of the transplanted heart.  N Engl J Med. 2002;  346 5-15
• 14 Stone G W, Grines C L, Cox D A, Garcia E, Tcheng J E, Griffin J J, Guagliumi G, Stuckey T, Turco M, Carroll J D. et al . Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.  N Engl J Med. 2002;  346 957-966
• 15 Strauer B E, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg R V, Kogler G, Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans.  Circulation. 2002;  106 1913-1918
• 16 Strauer B E, Brehm M, Zeus T, Gattermann N, Hernandez A, Sorg R V, Kogler G, Wernet P. Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction.  Dtsch Med Wochenschr. 2001;  126 932-938
• 17 Tomita S, Li R K, Weisel R D, Mickle D A, Kim E J, Sakai T, Jia Z Q. Autologous transplantation of bone marrow cells improves damaged heart function.  Circulation. 1999;  100 II247-256